HIV-1 Tat: Role in Bystander Toxicity

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2020 Mar 12

PMID 32158701

Citations 43

Authors

David Ajasin

Eliseo A Eugenin

Affiliations

Soon will be listed here.

Abstract

HIV Tat protein is a critical protein that plays multiple roles in HIV pathogenesis. While its role as the transactivator of HIV transcription is well-established, other non-viral replication-associated functions have been described in several HIV-comorbidities even in the current antiretroviral therapy (ART) era. HIV Tat protein is produced and released into the extracellular space from cells with active HIV replication or from latently HIV-infected cells into neighboring uninfected cells even in the absence of active HIV replication and viral production due to effective ART. Neighboring uninfected and HIV-infected cells can take up the released Tat resulting in the upregulation of inflammatory genes and activation of pathways that leads to cytotoxicity observed in several comorbidities such as HIV associated neurocognitive disorder (HAND), HIV associated cardiovascular impairment, and accelerated aging. Thus, understanding how Tat modulates host and viral response is important in designing novel therapeutic approaches to target the chronic inflammatory effects of soluble viral proteins in HIV infection.

Citing Articles

Additive Effects of Glutathione in Improving Antibiotic Efficacy in HIV- Co-Infection in the Central Nervous System: A Systematic Review.

Nabipur L, Mouawad M, Venketaraman V Viruses. 2025; 17(1).

PMID: 39861915 PMC: 11769047. DOI: 10.3390/v17010127.

The challenges to detect, quantify, and characterize viral reservoirs in the current antiretroviral era.

Gutierrez H, Eugenin E NeuroImmune Pharm Ther. 2025; 3(3-4):211-219.

PMID: 39845128 PMC: 11751450. DOI: 10.1515/nipt-2024-0017.

Examining the effects of the HIV-1 protein Tat and morphine on antiretroviral accumulation and distribution within the brain.

Jones A, Rademeyer K, Rosen E, Contaifer S, Wijesinghe D, Hauser K Clin Transl Sci. 2024; 17(10):e70035.

PMID: 39382215 PMC: 11462598. DOI: 10.1111/cts.70035.

Exploring HIV-1 Maturation: A New Frontier in Antiviral Development.

McGraw A, Hillmer G, Medehincu S, Hikichi Y, Gagliardi S, Narayan K Viruses. 2024; 16(9).

PMID: 39339899 PMC: 11437483. DOI: 10.3390/v16091423.

Immune Characteristics and Immunotherapy of HIV-Associated Lymphoma.

Liu Y, Xie X, Li J, Xiao Q, He S, Fu H Curr Issues Mol Biol. 2024; 46(9):9984-9997.

PMID: 39329948 PMC: 11429793. DOI: 10.3390/cimb46090596.

References

Barre-Sinoussi F, Ross A, Delfraissy J . Past, present and future: 30 years of HIV research. Nat Rev Microbiol. 2013; 11(12):877-83. DOI: 10.1038/nrmicro3132. View

Cross A, Woodroofe M . Chemokines induce migration and changes in actin polymerization in adult rat brain microglia and a human fetal microglial cell line in vitro. J Neurosci Res. 1999; 55(1):17-23. DOI: 10.1002/(SICI)1097-4547(19990101)55:1<17::AID-JNR3>3.0.CO;2-J. View

Zungsontiporn N, Tello R, Zhang G, Mitchell B, Budoff M, Kallianpur K . Non-Classical Monocytes and Monocyte Chemoattractant Protein-1 (MCP-1) Correlate with Coronary Artery Calcium Progression in Chronically HIV-1 Infected Adults on Stable Antiretroviral Therapy. PLoS One. 2016; 11(2):e0149143. PMC: 4750941. DOI: 10.1371/journal.pone.0149143. View

Prevedel L, Morocho C, Bennett M, Eugenin E . HIV-Associated Cardiovascular Disease: Role of Connexin 43. Am J Pathol. 2017; 187(9):1960-1970. PMC: 5809504. DOI: 10.1016/j.ajpath.2017.05.011. View

Rao V, Neogi U, Talboom J, Padilla L, Rahman M, Fritz-French C . Clade C HIV-1 isolates circulating in Southern Africa exhibit a greater frequency of dicysteine motif-containing Tat variants than those in Southeast Asia and cause increased neurovirulence. Retrovirology. 2013; 10:61. PMC: 3686704. DOI: 10.1186/1742-4690-10-61. View

Barre-Sinoussi F . Functional HIV cure is no pipe dream, says codiscoverer of the virus. BMJ. 2013; 346:f2947. DOI: 10.1136/bmj.f2947. View

Coll B, Parra S, Alonso-Villaverde C, de Groot E, Aragones G, Montero M . HIV-infected patients with lipodystrophy have higher rates of carotid atherosclerosis: the role of monocyte chemoattractant protein-1. Cytokine. 2006; 34(1-2):51-5. DOI: 10.1016/j.cyto.2006.03.013. View

Macquart C, Juttner R, Morales Rodriguez B, Le Dour C, Lefebvre F, Chatzifrangkeskou M . Microtubule cytoskeleton regulates Connexin 43 localization and cardiac conduction in cardiomyopathy caused by mutation in A-type lamins gene. Hum Mol Genet. 2018; 28(24):4043-4052. DOI: 10.1093/hmg/ddy227. View

Easley R, Van Duyne R, Coley W, Guendel I, Dadgar S, Kehn-Hall K . Chromatin dynamics associated with HIV-1 Tat-activated transcription. Biochim Biophys Acta. 2009; 1799(3-4):275-85. PMC: 2838975. DOI: 10.1016/j.bbagrm.2009.08.008. View

10.

Anand A, Rachel G, Parthasarathy D . HIV Proteins and Endothelial Dysfunction: Implications in Cardiovascular Disease. Front Cardiovasc Med. 2019; 5:185. PMC: 6305718. DOI: 10.3389/fcvm.2018.00185. View

11.

Yao H, Yang Y, Kim K, Bethel-Brown C, Gong N, Funa K . Molecular mechanisms involving sigma receptor-mediated induction of MCP-1: implication for increased monocyte transmigration. Blood. 2010; 115(23):4951-62. PMC: 2890169. DOI: 10.1182/blood-2010-01-266221. View

12.

Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P . Angiogenic potential in vivo by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. AIDS. 1994; 8(9):1237-44. DOI: 10.1097/00002030-199409000-00004. View

13.

Li W, Huang Y, Reid R, Steiner J, Malpica-Llanos T, Darden T . NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci. 2008; 28(47):12190-8. PMC: 6671692. DOI: 10.1523/JNEUROSCI.3019-08.2008. View

14.

Conant K, Garzino-Demo A, Nath A, McArthur J, Halliday W, Power C . Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proc Natl Acad Sci U S A. 1998; 95(6):3117-21. PMC: 19704. DOI: 10.1073/pnas.95.6.3117. View

15.

Urbinati C, Bugatti A, Giacca M, Schlaepfer D, Presta M, Rusnati M . alpha(v)beta3-integrin-dependent activation of focal adhesion kinase mediates NF-kappaB activation and motogenic activity by HIV-1 Tat in endothelial cells. J Cell Sci. 2005; 118(Pt 17):3949-58. DOI: 10.1242/jcs.02518. View

16.

Xiao H, Neuveut C, Tiffany H, Benkirane M, Rich E, Murphy P . Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci U S A. 2000; 97(21):11466-71. PMC: 17223. DOI: 10.1073/pnas.97.21.11466. View

17.

Chiozzini C, Toschi E . HIV-1 TAT and IMMUNE DYSREGULATION in AIDS PATHOGENESIS: a THERAPEUTIC TARGET. Curr Drug Targets. 2015; 17(1):33-45. DOI: 10.2174/1389450116666150825110658. View

18.

Wang T, Yi R, Green L, Chelvanambi S, Seimetz M, Clauss M . Increased cardiovascular disease risk in the HIV-positive population on ART: potential role of HIV-Nef and Tat. Cardiovasc Pathol. 2015; 24(5):279-82. PMC: 4831910. DOI: 10.1016/j.carpath.2015.07.001. View

19.

Joseph S, Arrildt K, Sturdevant C, Swanstrom R . HIV-1 target cells in the CNS. J Neurovirol. 2014; 21(3):276-89. PMC: 4366351. DOI: 10.1007/s13365-014-0287-x. View

20.

Heaton R, Franklin D, Ellis R, McCutchan J, Letendre S, LeBlanc S . HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2010; 17(1):3-16. PMC: 3032197. DOI: 10.1007/s13365-010-0006-1. View